2 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow T-Cell Lymphoma Relapsed: new trials by email Literature Review of T-Cell Lymphoma Relapsed trials Research Report on T-Cell Lymphoma Relapsed
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Venetoclax - T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory | Phase 2 | Terminated | Fondazione Italiana Linfomi - ETS | 22 | 2018-09-25 | 2023-12-12 |
| Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma Avelumab - T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory | Phase 2 | Completed | University of Birmingham | 35 | 2017-12-08 | 2024-07-16 |
| Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) IL-15 plus, alemtuzumab - T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL) | Phase 1 | Completed | National Cancer Institute (NCI) | 11 | 2017-01-19 | 2022-04-29 |
Immunoblastic Lymphadenopathy (1) · Leukemia, Prolymphocytic, T-Cell (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Lymphoma (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, Prolymphocytic (1) · Leukemia, T-Cell (1) · Lymphadenopathy (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1)
Alemtuzumab (1) · Interleukin-15 (1) · avelumab (1) · venetoclax (1)
Fondazione Italiana Linfomi - ETS (1) · National Cancer Institute (NCI) (1) · University of Birmingham (1)
Italy (1) · United Kingdom (1) · United States (1)
Francesco Zaja, MD (1) · Kevin Conlon, M.D. (1) · Simon Wagner, MD (1)